Search

everythinglearnresearchcommunity

for

Search:↓

Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.

The treatment combining platelet-rich plasma and a non-cross-linked hyaluronic acid compound significantly improved hair density and reduced bald areas in women with androgenetic alopecia, and it's safe with only mild side effects.

Hydroxychloroquine may help hair regrowth in alopecia universalis.

Areata-like lupus can mimic alopecia areata but is a form of cutaneous lupus erythematosus.

JAK inhibitors show promise in treating moderate to severe alopecia areata.

Microneedling mildly regrows hair in androgenetic alopecia but not in other types.

Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.

Fractional lasers and microneedling, combined with topical agents, could potentially treat Alopecia Areata effectively, but more research is needed due to limited data.

The PRP-like cosmetic with biomimetic peptides is potentially effective and safe for treating alopecia areata.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.

Higher IL-21 levels may help predict alopecia areata activity.

Tofacitinib taken by mouth helps treat hair loss in children.

Transepidermal drug delivery effectively treated areata alopecia with minimal side effects.

AGA might indicate higher risk for severe COVID-19.

Higher CD70 and CD27 gene expression in alopecia areata lesions predicts disease severity and activity.

Platelet-rich plasma treatment could potentially be an effective way to treat chronic alopecia areata with minimal side effects.

Omalizumab may cause temporary hair loss, especially in women aged 18-60.

Treating ovarian-related inflammation may help hair regrowth in women with alopecia areata.

Blocking certain proteins can significantly regrow hair in severe alopecia areata.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

5-ARI therapy may help prevent prostate cancer progression.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Despite progress in treatment, the exact cause of Alopecia areata is still unknown.

Eclipta alba (Bhringraj) helps protect the liver and promotes hair growth.

Platelet-Rich Plasma (PRP) is a low-risk treatment for Androgenic Alopecia (AGA) that generally improves hair count or density, but more research is needed for optimization.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

A complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide may help increase hair count in male pattern hair loss without side effects.